Business Wire

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System

30.1.2026 08:30:00 CET | Business Wire | Press Release

Share

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine.

In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market.

Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinical research. With over 3,000 peer- reviewed and published articles, the company currently has 32 ongoing global clinical study projects enrolling 600+ patients with over 2,000 study visits, treating a wide range of skin types and conditions.

The launch of the Glacē system, together with the upcoming launch of the Matrix and VBeam Pro systems, provides best-in-class treatment solutions for skin health including skin tightening, texture, acne, scars, advanced vascular treatments and overall skin quality.

The Glacē System is a professional facial system designed for high-frequency skin care for medical, wellness and aesthetic providers. Engineered as a comprehensive skin purifying platform, the Glacē system functions both as a standalone facial treatment and as a clinically proven adjunct to energy-based device treatments to support improved skin quality, patient comfort and consistent results. The Glacē system enables a broader segment of practices — spanning the range from beauty-focused to medical aesthetic practices, to offer a modern, repeatable skin health treatment while enhancing combination treatment outcomes for practices using Candela devices.

The Matrix System (currently pending EU MDR clearance) is Candela’s next-generation skin renewal workstation that combines intelligent, outcomes-driven energy delivery with safety-by-design engineering. The multiapplication radiofrequency (RF) platform integrates skin resurfacing, microneedling and noninvasive wrinkle treatment within a single device to address multiple layers of the skin with precision. Powered by Candela’s signature Aesthetic Intelligence technology, the Matrix system is designed to sense, adapt and display tissue impedance in real time, supporting safe, smooth and consistent heating across applications, skin types and depths. This intelligent performance allows providers to deliver reproducible outcomes across all skin types and a wide range of indications, notably skin tightening, acne scarring, textural irregularities and collagen loss.

The Vbeam Pro system, launched in 2025 in the U.S., is the only vascular laser FDA-cleared for use in pediatric patients. It combines an advanced 595 nm pulsed dye laser with a 1064 nm Nd:YAG wavelength to offer unmatched precision, accuracy and treatment versatility. The platform is designed to effectively treat a broad spectrum of skin conditions, including pediatric and adult vascular abnormalities, rosacea, port-wine stains, acne, leg veins, spider veins, scars, benign pigmented lesions, wrinkles, warts, stretch marks, and photoaging.

“Developing innovative products that powerfully enhance skin health and youthfulness is our passion. We are excited to be unveiling the Matrix, Glacē and VBeam Pro systems here,” said Geoffrey Crouse, Chief Executive Officer of Candela. “By launching these major platforms, we are accelerating our ability to serve customers in the fast-evolving European and global market, where patient demand continues to grow, and our scientific and clinically proven treatment solutions continue to uniquely address skin quality, laxity, texture, tone and more.”

As part of this next chapter of innovation, Candela is also unveiling experience-driven customer engagement — pairing scientific exchange with immersive brand experience designed to foster engagement with key opinion leaders, partners and customers, including exclusive clinical and customer experiences held in conjunction with IMCAS.

“As someone whose practices use both the Glacē and Matrix systems, I see these platforms as highly complementary,” said Firas Al-Niaimi, MD, Professor of Laser Dermatology and a Board-Certified Dermatologist with a private practice in London. “Together, they allow us to comprehensively address skin health — including skin laxity, texture and tone — safely with precision and confidence. Candela continues to invest not only in technology, but also in addressing the needs of a broader cross-section of aesthetic practices and their patients in clinically validated ways that meaningfully and positively impact our patient experience.”

Candela will showcase the Glacē, Matrix and VbeamPro Systemsat IMCAS 2026, featuring live product demonstrations, scientific presentations, a dedicated symposium on Epigenetics and Skin Health, and other engagement opportunities with its global clinical community.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260129455611/en/

Contacts

Sarvar Kothavala
VP, Global Advocacy, Professional Education & Strategic Insights
Mobile: +1.415.760.0902
Email: sarvark@candelamedical.com

Elena Yacoub
We. Communications
Office: +1.425.578.1757
Email: eyacoub@wecommunications.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye